ArticleActa pharmacologica Sinica2019

Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.

Ling-Jiao Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.